RankAlpha logo
Back to Rankings

VSTM

VerastemF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Commercial revenue is showing traction, funding reduces near-term financing pressure, and the October VS-7375 update could provide a material clinical validation point. The positive deterministic prior is supported by strong primary-source coverage, but the thesis remains event-driven.
Posture
Defensive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-25.
What can break
Commercial uptake, refills, reimbursement, and adverse-event management may not support the self-sufficiency target.
Momentum
99
Value
41
Sentiment
30
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $7.75 · Bull $10.50 · Bear $4.75Analysis 2026-08-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $17.22
Why
Momentum99 · Δ7d +1.5
Value41 · Δ7d -0.1
Sentiment30 · Δ7d -13.2
So what
Weak posture (Net Bullish). Prioritize risk control and patience.

Confirming evidence

  • • 3 setup hits (3d) with net bullish as of 2026-10-25.
  • • Value remains the lead driver in the composite, 7D delta -0.1.

Contradictions & invalidation

  • • Commercial uptake, refills, reimbursement, and adverse-event management may not support the self-sufficiency target.
  • • October VS-7375 data may fail to confirm sufficient response, durability, safety, or differentiation.
  • • The valuation is highly sensitive to October clinical differentiation, enrollment execution, and the ability to make the LGSOC franchise self-sustaining.

Catalyst clock

2026-11-07

VS-7375 October clinical update

Lead driver: Value · See fundamentals
Momentum
99
8% active weight
Current posture
7d trendFlat
Δ7d
+1.5
Δ21d
+0.2
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
30
45% active weight
Current posture
7d trendSoftening
Δ7d
-13.2
Δ21d
-32.6
Why this grade

Composite grade F. Momentum 98.5 / Value 40.6 / Sentiment 30.3

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-09. Scenario method

B+
Bull case
25%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-08-09 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$7.75
Analysis reference price unavailable
Analysis 2026-08-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-08-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.22B
Beta
0.42
Shares Out
121.5M
P/E (TTM) · Derived
-3.3
P/S (TTM)
39.62
P/FCF (TTM) · Derived
-5.51
Rev YoY
+1775.4%
EPS YoY
-44.6%
Gross Margin
+86.4%
Op Margin
-182.6%
Net Debt
-$117.82M
Current Ratio
2.25
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data